Clinical Trial Update: Efficacy and Safety of Taitacept in Treatment of Refractory or Recurrent Anti-NMDAR/anti-LGI1 Encephalitis [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the efficacy and safety of Taitacept in refractory or recurrent anti-N-methyl-D-aspartate receptor encephalitis and anti-LGI1 encepha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anti-lgi1 Encephalitis
• Anti-n-methyl-d-aspartate Receptor Encephalitis

Drugs mentioned

• Taitacept

Snippet

Sponsor: Beijing Tongren Hospital | Conditions: Anti-N-Methyl-D-Aspartate Receptor Encephalitis | Phase 2 | Status: RECRUITING